Related posts
BOC holds rate, TSX climbsTSX flat, Wall Street declines on hot employment numbersBostic derails rallyShares are down in the past 24 hours due to a delay in a drug approval. But another drug remains strong in sales, and they have double-digit in oncology drugs in trials. A great science company.
A quality company. Trades at 17x. The FDA is delaying approval of a drug, but that is correctable because the issue isn't about safety or efficacy.
Trades at 19x earnings, but have a huge drug pipeline.
Regeneron Pharmaceuticals Inc is a American stock, trading under the symbol REGN-Q on the NASDAQ (REGN). It is usually referred to as NASDAQ:REGN or REGN-Q
In the last year, 6 stock analysts published opinions about REGN-Q. 4 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Regeneron Pharmaceuticals Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
6 stock analysts on Stockchase covered Regeneron Pharmaceuticals Inc In the last year. It is a trending stock that is worth watching.
On 2023-12-01, Regeneron Pharmaceuticals Inc (REGN-Q) stock closed at a price of $814.86.
The momentum is waning, and last quarter revenue growth was only 14%. They're coming to the end of the road.